Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7496937rdf:typepubmed:Citationlld:pubmed
pubmed-article:7496937lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C0034819lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C1749467lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C0023689lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C0205160lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C1446409lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C0259931lld:lifeskim
pubmed-article:7496937lifeskim:mentionsumls-concept:C2826293lld:lifeskim
pubmed-article:7496937pubmed:issue2lld:pubmed
pubmed-article:7496937pubmed:dateCreated1996-1-16lld:pubmed
pubmed-article:7496937pubmed:abstractTextWe measured serum 2,5-oligoadenylate synthetase (2,5-AS) levels and soluble interleukin-2 receptor (sIL-2R) levels in human immune deficiency virus type 1 (HIV-1)-positive and HIV-1-negative hemophiliacs in order to clarify the clinical significance of these parameters in hemophiliacs. Serum 2,5-AS levels were measured by a radioimmunosorbent assay, and sIL-2R levels were measured by an enzyme-linked immunosorbent assay. The mean serum 2,5-AS levels were higher in AIDS-related-complex and AIDS patients, asymptomatic carriers, and HIV-1-negative hemophiliacs than in hepatitis C virus-positive patients and healthy controls. Serial determinations showed that the 2,5-AS levels tended to increase in HIV-1-positive patients, especially those with AIDS-related complex or AIDS, although it showed a substantial decrease in the terminal stage. The serum sIL-2R levels were higher in HIV-1-positive patients, HIV-1-negative patients, and hepatitis C virus-positive patients than in controls. Serial studies showed little change in the HIV-1-positive and HIV-1-negative groups, although sIL-2R levels showed a tendency to decrease with zidovudine treatment. On the basis of the present results, we may well conclude that 2,5-AS and sIL-2R are not specific markers for hemophiliacs with HIV-1 infection. However, serial measurement of these markers can still be useful for assessing the progression of AIDS and the prognosis for patients with AIDS, as well as for monitoring the response to zidovudine.lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:languageenglld:pubmed
pubmed-article:7496937pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:citationSubsetIMlld:pubmed
pubmed-article:7496937pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7496937pubmed:statusMEDLINElld:pubmed
pubmed-article:7496937pubmed:monthMarlld:pubmed
pubmed-article:7496937pubmed:issn1071-412Xlld:pubmed
pubmed-article:7496937pubmed:authorpubmed-author:GotohMMlld:pubmed
pubmed-article:7496937pubmed:authorpubmed-author:KinoshitaTTlld:pubmed
pubmed-article:7496937pubmed:authorpubmed-author:SaitohNNlld:pubmed
pubmed-article:7496937pubmed:authorpubmed-author:MatsudaJJlld:pubmed
pubmed-article:7496937pubmed:authorpubmed-author:TsukamotoMMlld:pubmed
pubmed-article:7496937pubmed:authorpubmed-author:GohchiKKlld:pubmed
pubmed-article:7496937pubmed:issnTypePrintlld:pubmed
pubmed-article:7496937pubmed:volume1lld:pubmed
pubmed-article:7496937pubmed:ownerNLMlld:pubmed
pubmed-article:7496937pubmed:authorsCompleteYlld:pubmed
pubmed-article:7496937pubmed:pagination155-9lld:pubmed
pubmed-article:7496937pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:meshHeadingpubmed-meshheading:7496937-...lld:pubmed
pubmed-article:7496937pubmed:year1994lld:pubmed
pubmed-article:7496937pubmed:articleTitleClinical significance of serum 2,5-oligoadenylate synthetase and soluble interleukin-2 receptor in hemophiliacs positive and negative for human immunodeficiency virus type 1.lld:pubmed
pubmed-article:7496937pubmed:affiliationDepartment of Medicine, Teikyo University School of Medicine, Tokyo, Japan.lld:pubmed
pubmed-article:7496937pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7496937pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed